Abstract:Topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research Background: CAR T cell therapy has significantly improved outcomes of patients with relapsed/refractory large B cell lymphoma (rrLBCL), but many do not experience long term benefit. The mechanisms of failure are multifaceted and includes CAR T-cell exhaustion. Understanding these mechanisms are likely to identify rational therapeutic avenues for improving outcomes. Aims: 1.To understand the impact of the rrLBCL immune microenvironment on clinical failure to CAR T therapy 2.Investigate targeting of CD38 with a novel CD38 T cell engaging trispecific antibody in combination with CD19 CAR T-cells Methods:Discovery analysis: 13 rrLBCL tumors, including 7 CAR T naïve and 6 CAR T refractory tumors, were subjected to scRNA-seq. Clustering was performed and frequency, clonal dominance, and expression profiles of major cell types and subclusters were compared between groups. Functional experiments: The effect of SAR442257 was assessed in cytotoxicity assays and compared to control antibodies lacking the CD38 or CD38/CD3/CD28 targeting regions. RL and HT lymphoma cell lines were CRISPR modified to knock-out CD19 and isogenic WT clones used as target cells. CD19 CAR T-cells were constructed from PBMCs of rrLBCL patients obtained at the time of apheresis using a construct like axicabtagene ciloleucel (axi-cel). For cytotoxicity assays, cell lines were co-cultured at E:T ratios of 1:1 for 24h or 48h. Results: scRNA-seq revealed that CAR T refractory rrLBCL tumors possessed significantly higher fractions of terminally exhausted LAG3+TIM3+CD38+ CD8 T-cells (CD8TEX) with high expression of T-cell dysfunction and TEX signatures compared to CAR T naïve tumors. CD8TEX were most frequent in CAR T refractory tumors and enriched within CAR+CD8 T-cells detected within all CAR T refractory tumors. We have previously identified similar cells enriched in axi-cel infusion products of rrLBCL patients failing to response (Deng et al., Nat. Med. 2020). TCR clonotype analysis revealed highly expanded T-cell clones within the CD8TEX cluster, significantly increased clonal dominance, and reduced clonal diversity of CD8TEX cells in CAR T refractory compared to CAR T naïve tumors. Single cell differential gene expression revealed significantly increased expression of LAG3, TIM3, and CD38 in CD8 T-cells from CAR T refractory compared to CAR T naïve tumors. We hypothesized that SAR442257, a CD38/CD28xCD3 trispecific antibody, could boost the activity of CD19 CAR T-cells from rrLBCL patients in part by allowing for dual antigen targeting of CD19 and CD38 on lymphoma cells and by inducing fratricide of CD38-expressing CD8TEX cells. Cytotoxicity assays showed that SAR442257 significantly increased the killing of CAR T-cells against HT and RL WT (CD19+/CD38+) cells (24-hr HT P-value=3e-4, 24-hr RL P-value=1e-2) which persisted at 48 hours. Addition of SAR442257 to CAR T-cells allowed killing of HT and RL CD19KO (CD19-/CD38+) (24-hr HT P-value=8e-7, 24-hr RL P-value=2e-8) at a level similar to the combination in WT cells. Addition of antibodies lacking CD38 or CD38/CD3/CD28-targeting regions did not boost CAR T cytotoxicity or rescue killing of CD19KO targets. We observed significant T-cell fratricide, which was beneficial or non-detrimental in light of significantly increased lymphoma cell killing. Summary/Conclusion: The tumor microenvironment of CAR T refractory rrLBCL is enriched in clonally expanded and terminally exhausted CD8 T-cells expressing CD38. The CD38/CD28xCD3 trispecific antibody SAR442257 boosted CAR T-cell activity through recognition of CD38 on the tumor, costimulation of CAR T-cells, and induced fratricide of CD38+ T-cells; resulting in superior tumor cell killing. In addition, SAR442257 allowed CD19 CAR T-cells to kill CD19-/CD38+ LBCL cells. Keywords: Diffuse large B cell lymphoma, Cellular therapy, Lymphoma therapy, CAR-T

Abstract 1528: Discovery and Preclinical Characterization of Fratricide-Resistant TRuC T-cells Targeting CD70

Single-cell analysis for the survival mechanisms of fratricidal CAR-T targeting T-cell malignancies

Abstract 4: Identifying novel patient-derived T cell receptors targeting TP53 public neoantigens

Abstract 2357: T cell receptor beta chain-directed Tri-specific antibody molecules retarget V-beta T cell subsets to tumors to promote potent and durable antitumor activity

Abstract 4021: The development of CAR T cell therapeutics targeting tumor specific CD146

T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape

Abstract 891: CD70-targeting CAR-T and CAR-NK cells demonstrate potent activity against NSCLC drug-tolerant persister cells

Abstract 718: CCR8 antibody drug conjugates: Targeting regulatory T cells for tumor sensitization

Abstract 3598: A new strategy for T cell therapy: T cells secreting TCR anti-CD3 bispecific T-cell engager

Abstract 3191: FT516, an Off-the-shelf Engineered NK Cell Therapeutic Product for Universal Anti-Tumor Targeting Strategy in Combination with Monoclonal Antibodies

P1366: SAR442257, A CD38/CD28/CD3 TRISPECIFIC ANTIBODY, POTENTIATES CAR T-CELL ACTIVITY AGAINST LARGE B-CELL LYMPHOMA

Abstract 26: An HLA-class II restricted HPV18 E7 specific TCR cloned from a long-term surviving cervical cancer patient

Abstract 1784: FGFR4 and CD276 dual targeting CAR T cells demonstrate synergistic antitumor activity in childhood rhabdomyosarcoma

Abstract 3995: A novel chimeric Fas signal redirect receptor enhances the durability of anti-tumor activity and serial killing potential of CAR T cells

Abstract 6717: Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies

Abstract 6704: Development and characterization of a tri-specific selective CD8 T cell engager (CD8xCD3xCD19) for treatment of B cell lymphoma

Abstract 7042: Enhancing TCR T cell function in solid tumors through in vivo combinatorial screens and single-cell analysis

Abstract 56: Preclinical in vivo characterization underpinning LGR5-targeting CAR-T cells as a cancer immunotherapy

Abstract 6721: AI-guided generation of novel GUCY2C-targeting T-cell engagers for the treatment of colorectal cancer

Abstract 10: Non-viral engineered T cell therapy specific for the hotspot mutation p53 R175H that integrates signal 1 (TCR), signal 2 (co-stimulation) and signal 3 (cytokine) and co-opts FasL-dependent apoptosis to achieve a coordinated antitumor CD4/8 T cell response

Abstract 6350: 2MW4691, a novel CCR8/CTLA-4 bispecific antibody, displays potent anti-tumor efficacy by specifically depeleting tumor-infiltrating Tregs and blocking CTLA-4 signaling on CD8+ T cells